Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of allogeneic adipose-derived mesenchymal stem cells in hyaluronic acid hydrogel for fecal incontinence
2021-002331-34Phase 2Active
- Sponsor
- Fundación IMABIS
- Start
- Mar 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSCC_ASC in fecal incontinence (FI) (3 arms), sponsored by Fundación IMABIS. Primary endpoint: Safety through 12 months. Started Mar 2022; status: active.
02
Drugs
CSCC_ASC
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on 2021-002331-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002331-34.